LamKap Bio alpha to present data on NILK-2301 & NILK-3301 programs

On August 8, 2022 The European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) will host the ESMO (Free ESMO Whitepaper) congress 2022 September 9-13, 2022 (Press release, LamKap Bio Group, AUG 8, 2022, View Source [SID1234618009]). LamKap Bio alpha reported to present for the first time preclinical data on the development of NILK-2301 (CEAxCD3) and NILK-3301 (CEAxCD28) bispecific antibodies for immunotherapy of patients with carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5 aka CEA) expressing solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Novel CEAxCD3 (NILK-2301) and CEAxCD28 (NILK-3301) κλ bispecific antibodies for next generation immunotherapy of CEA-expressing cancer" will be presented on site in Hall 4 (poster area) on September 12 (presentation no. 752P).

A pdf file will be made available for download after presentation at the meeting.